Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Vasculitic neuropathy-related disability, pain, quality of life, and autonomic symptoms: A survey of 312 patients.

Collins MP. et al, (2024), Rheumatology (Oxford)

2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis

Grayson PC. et al, (2022), Arthritis & Rheumatology, 74, 1872 - 1880

2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis

Ponte C. et al, (2022), Arthritis & Rheumatology, 74, 1881 - 1889

2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.

Grayson PC. et al, (2022), Arthritis & rheumatology (Hoboken, N.J.)

2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.

Ponte C. et al, (2022), Arthritis & rheumatology (Hoboken, N.J.)

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis.

Ponte C. et al, (2022), Annals of the rheumatic diseases

2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.

Grayson PC. et al, (2022), Annals of the rheumatic diseases

Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis.

Gribbons KB. et al, (2020), Arthritis care & research, 72, 1615 - 1624

Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease.

Goodchild G. et al, (2020), Clinical medicine (London, England), 20, e32 - e39

Early development of new cardiovascular risk factors in the systemic vasculitides.

Monti S. et al, (2020), Clinical and experimental rheumatology, 38 Suppl 124, 126 - 134

2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Hellmich B. et al, (2020), Annals of the rheumatic diseases, 79, 19 - 30

Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides: Insights from the DCVAS study.

Bischof A. et al, (2019), Neurology(R) neuroimmunology & neuroinflammation, 6

Rheumatoid factor testing in Spanish primary care: A population-based cohort study including 4.8 million subjects and almost half a million measurements

Morsley K. et al, (2019), Reumatología Clínica, 15, 350 - 354

Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis.

Gibson KM. et al, (2019), Arthritis & rheumatology (Hoboken, N.J.), 71, 1747 - 1755

Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis.

Tomasson G. et al, (2019), The Journal of rheumatology, 46, 928 - 934

Giant cell arteritis: new concepts, treatments and the unmet need that remains

Coath F. et al, (2019), Rheumatology, 58, 1123 - 1125

Giant cell arteritis: new concepts, treatments and the unmet need that remains.

Coath F. et al, (2019), Rheumatology (Oxford, England), 58

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIRUKUMAB IN THE TREATMENT OF PATIENTS WITH GIANT CELL ARTERITIS

Schmidt W. et al, (2019), ANNALS OF THE RHEUMATIC DISEASES, 78, 827 - 827

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.

Jayne D. et al, (2019), Arthritis & rheumatology (Hoboken, N.J.), 71, 952 - 963

HOW TO ASSESS PATIENT WITH SUSPECTED VASCULITIS

Luqmani R., (2019), ANNALS OF THE RHEUMATIC DISEASES, 78, 36 - 37

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?